IRulya Therapeutics, Inc. (IRLA)
38.01
+4.24
(+12.54%)
USD |
NASDAQ |
Nov 10, 16:00
38.01
0.00 (0.00%)
After-Hours: 20:00
IRulya Therapeutics Cash from Operations (Annual) : -41.42M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | -41.42M |
| December 31, 2024 | -31.90M |
| December 31, 2023 | -18.29M |
| December 31, 2022 | -44.04M |
| December 31, 2021 | -62.93M |
| Date | Value |
|---|---|
| December 31, 2020 | -50.82M |
| December 31, 2019 | -33.28M |
| December 31, 2018 | -11.70M |
| December 31, 2017 | -9.827M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| Korsana Biosciences, Inc. | -3.314M |
| PepGen Inc. | -81.64M |
| Q32 Bio, Inc. | -33.54M |
| Bridgebio Oncology Therapeutics, Inc. | -113.89M |
| Arrowhead Pharmaceuticals, Inc. | 179.55M |